CD274 and non-small cell lung carcinoma: Thus, the addition of pembrolizumab to platinum‐based chemotherapy in patients with previously untreated advanced NSCLC has recently produced a significant improvement in survival outcomes, independent of PD‐L1 expression [7, 8].